MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Clinical trials for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) explained in plain language.
Never miss a new study
Get alerted when new MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) trials appear
Sign up with your email to follow new studies for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive 'Tumor Seeker' drug enters first human trials for tough cancers
Disease control Recruiting nowThis is a first-in-human study testing a new experimental drug called 212Pb-DOTAM-GRPR1 in adults with advanced cancers that have returned or spread. The main goal is to find a safe and tolerable dose. Researchers will also check if the drug, which delivers radiation directly to …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Orano Med LLC • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for men with Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new drug called Pocenbrodib to see if it is safe and can help control advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. Researchers will give Pocenbrodib alone or combined with other cancer drugs to about …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Pathos AI, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New cancer drug enters human testing for advanced tumors
Disease control Recruiting nowThis is the first study in people to test a new drug called MHB048C for advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug shows early signs of helping to control the cancer. The study will enroll about…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo attack on Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug (SHR-1701) to precise, high-dose radiation (SBRT) can better control advanced prostate cancer that has spread and stopped responding to standard hormone therapy. It will involve about 66 men to see if this combination …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for Tough-to-Treat prostate cancer: first human trial begins
Disease control Recruiting nowThis is the first study in people to test a new drug called ACE-232 for men with metastatic prostate cancer that has stopped responding to standard hormone therapy. The main goal is to find a safe dose and see how the body handles the drug. Researchers will also look for early si…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug trial offers hope for men with aggressive prostate cancer
Disease control Recruiting nowThis is the first study in people testing a new drug called KTX2001 for advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give the drug alone and combined with an existing medication (darolutamide) to about 144 men to…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New combo therapy trial targets aggressive prostate cancer
Disease control Recruiting nowThis study is testing whether adding enzalutamide to talazoparib works better than talazoparib alone for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial includes 126 men whose cancer has specific genetic changes and …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Mar 04, 2026 15:29 UTC
-
Scientists scan to see why prostate cancer fights back
Knowledge-focused Recruiting nowThis study aims to understand why some tumors in a patient with advanced prostate cancer stop responding to treatment while others may still be controlled. Researchers will use a series of specialized PET scans on 45 participants to track individual tumors before, during, and aft…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: NA • Sponsor: Frederic Pouliot • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC